ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
September 10 2015 - 11:45AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced the Company will
participate in the Morgan Stanley Global Healthcare Conference.
ImmunoGen President and CEO Daniel Junius will discuss
the Company in a “fireside chat” moderated question and answer
session that will be webcast beginning at 2:50 pm ET on
September 16, 2015.
This webcast will be accessible live through the "Investors"
section of the Company's website, www.immunogen.com; a replay
will be available at the same location for approximately a
week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150910006252/en/
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024